Taofeek Owonikoko
University of Maryland, Baltimore · Emory University · ECOG-ACRIN Cancer Research Group
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Taofeek Owonikoko as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:50 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07057791 · Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung CancerPrECOG, LLC. · recruiting · Extensive Stage Lung Small Cell Cancer · study chair
- Ph2NCT05450965 · Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung CancerUniversity of Maryland, Baltimore · recruiting · Small-cell Lung Cancer, Small Cell Lung Carcinoma · principal investigator
- Ph1NCT05403723 · Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLCUniversity of Maryland, Baltimore · suspended · Extensive-stage Small-cell Lung Cancer · principal investigator
- Ph2NCT02701400 · Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung CancerEmory University · completed · Recurrent Small Cell Lung Carcinoma · principal investigator
- Ph1/Ph2NCT01642251 · Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung CancerNational Cancer Institute (NCI) · completed · Extensive Stage Small Cell Lung Carcinoma, Large Cell Lung Carcinoma, Neuroendocrine Carcinoma · principal investigator
- Ph1NCT01470209 · A Phase I Study of BKM120 and Everolimus in Advanced Solid MalignanciesEmory University · completed · Solid Tumors, Lung Cancer · principal investigator
- Ph2NCT01470248 · Study of Arsenic Trioxide in Small Cell Lung CancerEmory University · completed · Lung Cancer, Cancer of Lung, Pulmonary Cancer · principal investigator
- Ph2NCT01270321 · Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid CancerEmory University · completed · Thyroid Cancer · principal investigator
- Ph1NCT01218555 · Study of Everolimus (RAD001) in Combination With LenalidomideEmory University · completed · Solid Organ Malignancies, Adenoidcystic Carcinoma, Neuroendocrine Tumors · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:50 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Advancing Oncologic Research Communities in Health Equity (ARCH) K12 ProgramK12CA301384 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · fiscal years 2025 to 2026 · $811,194 awarded in 2026Same name and institution; not confirmed by an ID
- Developmental FundsP30CA134274 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · fiscal years 2023 to 2026 · $179,422 awarded in 2026Same name and institution; not confirmed by an ID
- Targeting polo-like kinase 1 (PLK1) for treatment of small cell lung cancerR01CA273216 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · fiscal years 2022 to 2026 · $646,115 awarded in 2026Grant number is on one of their registry trials
- Novel systemic therapy to improve clinical outcome in small cell lung cancerK23CA164015 · NCI · EMORY UNIVERSITY · fiscal years 2011 to 2015 · $162,667 awarded in 2015Grant number is on one of their registry trials
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- ECOG-ACRIN Network Group Operations CenterU10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · fiscal years 2014 to 2026Named on NCT01642251
- Eastern Cooperative Oncology Group Operations OfficeU10CA021115 · NCI · FRONTIER SCI & TECHNOLOGY RSCH FDN, INC · PI ROBERT L COMIS · fiscal years 1985 to 2013Named on NCT01642251
- ECOG-ACRIN Biospecimen Bank to Support NCTNU24CA196172 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI STANLEY R. HAMILTON, Scott D Jewell · fiscal years 2015 to 2026Named on NCT01642251
Most cited trial papers
Clinical-trial papers with this author name in non-small cell lung cancer, ranked by citations from NIH iCite, fetched 2026-11-12 11:50 UTC. The ranking covers the 200 most relevant of 10 PubMed records, and a shared surname and initials can bring in a namesake. All 10 on PubMed
- Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer.N Engl J Med · 2023529 citationsRCR 41.5
- 118 citationsRCR 3.4
- Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase I Study.J Thorac Oncol · 201752 citationsRCR 1.5
- Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial).Ann Oncol · 201347 citationsRCR 1.3
- Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer.J Clin Oncol · 201544 citationsRCR 1.2
- Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer.J Thorac Oncol · 201337 citationsRCR 0.9
- 33 citationsRCR 0.7
- Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G.Clin Lung Cancer · 202127 citationsRCR 1.1
- A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer.Clin Cancer Res · 201521 citationsRCR 0.6
- A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non-Small-Cell Lung Cancer (NSCLC) who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade.Clin Lung Cancer · 202212 citationsRCR 0.5